The study by Gialamas and colleagues is an and up-to-date systematic review and meta-analysis on the impact of cardiovascular and/or lung comorbidities in patients with pulmonary arterial hypertension (PAH), previously referred to as patients with “atypical PAH”. This subgroup has been increasingly recognised in recent years due to their distinct clinical characteristics and challenges in management. The meta-analysis reveals the significant impact of comorbidities on the mortality of PAH patients. Additionally, the critical need for novel and more personalized treatment approaches tailored to this emerging patient population is highlighted
Our mission: To reduce the burden of cardiovascular disease.